Human Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B) Protein

Product Graph
234€ (5 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Human Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx073456
tested applications
SDS-PAGE

Description

Human Cyclin-Dependent Kinase Inhibitor 1B Protein is a recombinant protein kinases.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Proteins and Peptides
Immunogen Target
Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B)
Host
E. coli
Recommended Dilution
Optimal dilutions/concentrations should be determined by the end user.
Origin
Human
Expression
Recombinant
Purity
> 90% (SDS-PAGE)
Size 1
5 µg
Size 2
20 µg
Size 3
1 mg
Form
Liquid
Tested Applications
SDS-PAGE
Availability
Shipped within 5-10 working days.
Storage
Store at 4 °C if the entire vial will be used within 2-4 weeks. Store at -20 °C for long term storage. For long term storage, it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P46527
Background
Protein CDKN1B
Status
RUO
Note
This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

Related Products

EH4327

Human CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit

Ver Producto
EM0914

Mouse CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit

Ver Producto
FNab06068

CDKN1B antibody

CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.

Ver Producto